CCL2 and cancer: The fourth factor with potential role in cancer radioresistance, a chemokine CCL2/MCP1 critical for monocyte and MDSC recruitment, showed 1.06-fold increase after 7 weeks of CMT (p = 0.0017) and then decreased after patients completed therapy (Figure 1D).